CASI Pharmaceuticals 향후 성장

Future 기준 점검 0/6

CASI Pharmaceuticals은 연간 수입과 매출이 각각 22.5%와 6.4% 증가할 것으로 예상되고 EPS는 연간 27.5%만큼 증가할 것으로 예상됩니다.

핵심 정보

22.5%

이익 성장률

27.49%

EPS 성장률

Biotechs 이익 성장	22.5%
매출 성장률	6.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	09 Dec 2025

최근 향후 성장 업데이트

Recent updates

Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop

Nov 25

Little Excitement Around CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues As Shares Take 43% Pounding

Sep 30

One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates

Sep 09

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Bounce 80% But Its Business Still Trails The Industry

Aug 16

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jul 02

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business

Mar 21

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

Nov 26

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25

이익 및 매출 성장 예측

NasdaqCM:CASI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	N/A	-28	N/A	N/A	1
12/31/2027	N/A	-27	N/A	N/A	1
12/31/2026	N/A	-25	N/A	N/A	1
12/31/2025	13	-41	N/A	N/A	1
9/30/2025	27	-49	N/A	N/A	N/A
6/30/2025	32	-47	N/A	N/A	N/A
3/31/2025	31	-40	N/A	N/A	N/A
12/31/2024	29	-39	-29	-29	N/A
9/30/2024	22	-31	N/A	N/A	N/A
6/30/2024	23	-27	-27	-25	N/A
3/31/2024	29	-30	N/A	N/A	N/A
12/31/2023	34	-27	-22	-20	N/A
9/30/2023	42	-40	N/A	N/A	N/A
6/30/2023	44	-41	-25	-21	N/A
3/31/2023	42	-38	N/A	N/A	N/A
12/31/2022	43	-41	-27	-21	N/A
9/30/2022	37	-27	-35	-28	N/A
6/30/2022	35	-32	-35	-25	N/A
3/31/2022	33	-31	-34	-23	N/A
12/31/2021	30	-37	-42	-27	N/A
9/30/2021	26	-45	-44	-27	N/A
6/30/2021	22	-52	-54	-30	N/A
3/31/2021	17	-54	-53	-29	N/A
12/31/2020	15	-48	-43	-26	N/A
9/30/2020	12	-47	-41	-23	N/A
6/30/2020	10	-40	-29	-21	N/A
3/31/2020	8	-46	-36	-23	N/A
12/31/2019	4	-46	-37	-23	N/A
9/30/2019	3	-43	-42	-34	N/A
6/30/2019	N/A	-42	N/A	-33	N/A
3/31/2019	N/A	-32	N/A	-28	N/A
12/31/2018	N/A	-27	N/A	-29	N/A
9/30/2018	N/A	-23	N/A	-15	N/A
6/30/2018	N/A	-16	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-11	N/A
12/31/2017	N/A	-11	N/A	-6	N/A
9/30/2017	N/A	-8	N/A	-7	N/A
6/30/2017	N/A	-8	N/A	-7	N/A
3/31/2017	N/A	-9	N/A	-6	N/A
12/31/2016	N/A	-9	N/A	-6	N/A
9/30/2016	N/A	-8	N/A	-6	N/A
6/30/2016	N/A	-8	N/A	-6	N/A
3/31/2016	0	-7	N/A	-6	N/A
12/31/2015	0	-7	N/A	-6	N/A
9/30/2015	0	-7	N/A	-5	N/A
6/30/2015	0	-27	N/A	-5	N/A
3/31/2015	0	-27	N/A	-4	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CASI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CASI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CASI 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CASI 의 수익(연간 6.4%)이 US 시장(연간 10.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: CASI 의 수익(연간 6.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CASI의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/27 13:33
종가	2026/01/27 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

CASI Pharmaceuticals, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Nathaniel Calloway	Edison Investment Research
Sean Lee	H.C. Wainwright & Co.
Mi Zhou	Maxim Group

CASI Pharmaceuticals 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 12%

Consensus revenue estimates fall by 17%

Consensus revenue estimates decrease by 33%

Consensus revenue estimates fall by 67%

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

CASI Pharmaceuticals Reports the Failure to Renew the Import Drug Registration License for FOLOTYN in China

CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC

Consensus EPS estimates fall by 12%

Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop

New major risk - Shareholder dilution

Third quarter 2025 earnings released: US$0.68 loss per share (vs US$0.55 loss in 3Q 2024)

Little Excitement Around CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues As Shares Take 43% Pounding

CASI Pharmaceuticals, Inc. Announces Appointment of James Huang as an Independent Director Effective as of October 1, 2025

One CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall by 17%

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Bounce 80% But Its Business Still Trails The Industry

New major risk - Share price stability

CASI Pharmaceuticals, Inc., Annual General Meeting, Aug 20, 2025

CASI Pharmaceuticals Announces CEO Changes

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Not Doing Enough For Some Investors As Its Shares Slump 30%

New minor risk - Share price stability

Consensus revenue estimates decrease by 33%

New minor risk - Negative shareholders equity

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Discontinuation of Litigation and Arbitration Demand with Acrotech

Full year 2024 earnings released: US$2.56 loss per share (vs US$2.02 loss in FY 2023)

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business

CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection (AMR) of Kidney Transplant

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34%

New minor risk - Share price stability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. Announces Change of Senior Management Positions

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO

CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.

CASI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 67%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug (IND) Application for CID-103 in Immune Thrombocytopenia

New minor risk - Profitability

CASI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China

CASI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 20, 2024

Casi Pharmaceuticals Announces First Dose of Folotyn in China

CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer

CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2024

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CASI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China

Consensus forecasts updated

Forecast to breakeven in 2024

Price target decreased to US$18.33

Insufficient new directors

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Consensus forecasts updated

Price target decreased to US$22.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations